Table 5

Statistical parameters characterizing the results obtained from Kaplan-Meier survival curves for PD. Characterization of Parkinson's Disease Incidence in the Statin Groups and CV Comparator

Dementia cases

Time to incidence for dementia cases (months)

Time to end of study for non-dementia cases (months)

Drug

Sample size (n)

n

%

Mean

SD

Mean

SD

Model 3: HR for incidence of dementia vs CV (95% CI)

CV

392 966

2417

0.62

19.5

8.0

30.3

8.6

Atorvastatin

53 701

224

0.42

17.9

7.7

24.0

11.5

0.99 (0.86–1.14)

Lovastatin

53 711

350

0.65

18.8

7.9

29.7

8.1

1.09 (0.98–1.22)

Simvastatin

725 820

2116

0.29

19.3

7.9

29.1

8.0

0.51 (0.49–0.55)

Column 1, medication group; column 2, sample size; column 3, number of dementia cases recorded during the course of the analytic period; column 4, percentage of PD cases (calculated by dividing the value in column 3 by that in column 2); columns 5 and 6, number of months between start of the analytic period and incidence of dementia, and standard deviation (SD); columns 7 and 8, number of months between start of the analytic period and point at which subjects not receiving a diagnosis of PD were censored due to the end of the analytic period, and SD.

Hazard ratio for incidence of PD based on the results from model 3 (Table 4).

Wolozin et al. BMC Medicine 2007 5:20   doi:10.1186/1741-7015-5-20